Compare Abeona Therapeutics Inc (ABEO) vs Southwest Airlines Co (LUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Southwest Airlines Co — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Southwest Airlines Co trades at $48.53 (market cap $24.16B). The key difference: Southwest Airlines Co is far larger — about 64.7× Abeona Therapeutics Inc's market cap, and Southwest Airlines Co pays a 1.46% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LUV | |
|---|---|---|
Market Cap | $373.32M | $24.16B |
Sector | Health | Industrials |
52-Week High | $7.23 | $54.80 |
52-Week Low | $4.17 | $29.06 |
Enterprise Value | $228.22M | $27.23B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Southwest Airlines (LUV) trades at $49.43, down 1.63% today, with a bullish technical signal from moving averages. The company reported revenue of $28.06B in 2025, with a net income margin of 2.83%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights sector optimism due to lower fuel costs and strong travel demand, with analyst consensus leaning toward a buy rating and a $52.47 price target.
The outlook for LUV is cautiously optimistic, supported by earnings growth potential and favorable industry trends, but risks include volatile fuel prices and competitive pressures. The stock presents a moderate opportunity for investors seeking exposure to the airline sector, with upside to the consensus target but sensitivity to macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
